Lv1
70 积分 2021-04-26 加入
The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China
1个月前
已完结
[Guideline for HER2 testing in breast cancer (2024 version)]
7个月前
已完结
Multiple myeloma
8个月前
已关闭
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial
1年前
已关闭
Sant M, Allemani C, Tereanu C, et al; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734
1年前
已完结
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
1年前
已关闭
皖公网安备34019202002308
